* Low-density lipoproteins
(LDL) carry cholesterol throughout the body.
Evaluating the atherogenic burden of individuals with a Friedewald-estimated low-density lipoprotein
cholesterol <70 mg/dL compared with a novel low-density lipoprotein
Determination of oxidized low-density lipoproteins
(ox-LDL) versus ox-LDL/beta2GPI complexes for the assessment of autoimmunemediated atherosclerosis.
This range also includes the intermediate density lipoprotein (IDL) and very low-density lipoprotein
Hyperlipidemia, with high low-density lipoprotein
cholesterol and triglycerides, and low high-density lipoprotein cholesterol levels (<40 mg/dL in men and <45 mg/dL in women), is a known major cardiovascular risk factor.
The most common reasons for high triglycerides include being overweight, lack of exercise, the metabolic syndrome, type 2 diabetes, and familial combined hyperlipidemia, which results in high triglycerides, high "bad" (low-density lipoprotein
, or LDL) cholesterol, and low "good" (high-density lipoprotein, or HDL) cholesterol.
Association of high-density lipoprotein cholesterol with incident cardiovascular events in women, by low-density lipoprotein
cholesterol and apolipoprotein B100 Levels: a cohort study.
Oral Trilipix[R] (fenofibric acid) helps to reduce levels of triglycerides and low-density lipoprotein
(LDL, or bad) cholesterol levels and to increase high-density lipoprotein (HDL, or good) cholesterol.
The biopharmaceutical company develops cholesterol-lowering drugs for the treatment of cardiovascular and metabolic disease, specifically targeting elevated LDL (low-density lipoprotein
, also known as "bad" cholesterol) levels.
Greater exposure to tobacco smoke was also associated with higher levels of a biological marker for "bad" cholesterol, or low-density lipoprotein
CETP is a protein that shuttles cholesterol throughout the body, thus controlling the levels of HDL, low-density lipoprotein
(LDL), and very-low-density lipoprotein (VLDL) in the blood.
Most health warnings involve low-density lipoprotein
(LDL), or "bad" cholesterol, which helps form hard deposits in the arteries called atherosclerotic plaques.
Albert Einstein College of Medicine of Yeshiva University (Bronx, NY) has patented methods of using of the sizes and levels of high-density lipoprotein (HDL) and low-density lipoprotein
(LDL) particles, the -641 allele of the promoter of the gene encoding apolipoprotein C-3 (APOC-3), the 405 allele of the gene encoding cholesteryl ester transfer protein (CETP), and plasma levels of insulin-like growth factor-1 (IGF-1), adiponectin, CETP and APOC-3, for determining and increasing an individual's likelihood of longevity and of retaining cognitive function during aging, and for determining and decreasing an individual's likelihood of developing a cardiovascular-, metabolic- or age-related disease.
Other cardiovascular goals for individuals with pre-diabetes and diabetes include a low-density lipoprotein
(LDL or "bad" cholesterol) level of under 100 mg/dl and a high-density lipoprotein (HDL or "good" cholesterol) level of more than 40.